January 31, 2024 · Form 4 insider transaction
Onyia Jude sold 126 shares of Neurocrine Biosciences, Inc. at $141.94 per share, a transaction worth $17.9K. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 2 days after the transaction.
Sale of 126 shares of common stock issued upon vesting of 237 restricted stock units on January 31, 2024 to cover payroll and withholding taxes, with the balance of the shares (111) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 1, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.